TP53 alterations are known to drive genomic instability, promote tumor progression, and contribute to therapy resistance, raising important questions about how these genetic disruptions impact survival outcomes and treatment responses in early‐onset CRC. The gene discussed is TP53; the disease is colorectal carcinoma.